I. MODIFIED AGREEMENTS | |||
Biotech Co.* (Country; Symbol) | Pharma Co. (Country) | Change from original agreement | Terms/Details (Date) |
Bio-Rad Laboratories Inc. (AMEX:BIO) | Beckman Coulter Inc. | Extended for eight years their development and manufacturing agreement in immunodiagnostic testing for blood virus and infectious disease | Bio-Rad will develop new immunoassays for Beckman Coulter's UniCel and Access immunoassay systems, including hepatitis B envelope antigen and antibody, to be used as indicators of chronic hepatitis or active infection (5/31) |
Inspire Pharmaceuticals Inc. (ISPH) | FAES Farma SA (Spain) | Amended licensing agreement for the U.S. and Canadian development and commercialization of oral bilastine to treat allergic rhinitis | FAES has agreed to conduct additional clinical work and an expanded QT/QTc comparative trial (6/20) |
Memory Pharmaceuticals Corp. (MEMY) | F. Hoffmann-La Roche Ltd. (Switzerland) | Expanded development agreement for MEM3454 to treat cognitive impairment associated with schizophrenia | Further details were not disclosed (6/19) |
II. TERMINATED AGREEMENTS | |||
Altus Pharmaceuticals Inc. (ALTU) | Dr. Falk Pharma GmbH (Germany) | Terminated agreement for ALTU-135 | Companies ended their development and commercialization collaboration in Europe and countries of the former Soviet Union, Israel and Egypt; Dr. Falk will transfer the orphan medicinal product designation and Altus will pay $16M over three years (6/11) |
Coley Pharmaceutical Group Inc. (COLY) | Pfizer Inc. | Terminated agreement for the lung cancer drug, PF-3512676 | The decision to terminate was made after the product showed no evidence of clinical efficacy in Phase III trials (6/20) |
Icagen Inc. (ICGN) | McNeil Consumer & Specialty Pharmaceuticals (subsidiary of Johnson & Johnson) | Terminated partnership for senicapoc | In April, Icagen halted a Phase III trial of senicapoc in adults with sickle cell disease after a data monitoring committee said the trial was unlikely to meet its primary endpoint of reducing crisis rate (6/22) |
| |||
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. AMEX = American Stock Exchange. | |||